key: cord-0704304-ijtq5731 authors: Mosconi, Maria Giulia; Caso, Francesco; Maraziti, Giorgio; Kremer, Christine; Costa, Luisa; Scarpa, Raffaele; Giacomelli, Roberto; Caso, Valeria title: Autoimmune screening before adenovirus vector-based DNA vaccine in women may avoid underuse for all the subjects date: 2021-10-05 journal: Neurol Sci DOI: 10.1007/s10072-021-05620-5 sha: b060a2e0ef3f83e68a576fae00315df0b5af5918 doc_id: 704304 cord_uid: ijtq5731 nan Whereas of March 31 2021, European Union countries had administered a total of 33,385,052 vaccinations, including 5,181,905 women under 50 years of age. The reported incidence of CVST with ITT was 44/5,181,905 (8.5 cases/ million) and the reported overall incidence of venous thrombotic events was 79/5,181,905 (15 cases/million people) [2] . In line with previous research reporting sex differences in vaccine responses, women exhibited a more significant immune response that might facilitate vaccine efficacy, but they also experienced more frequent and more severe adverse events (AEs) [3] [4] [5] . The interim analysis of phase 1/2/3 ongoing AZD1222 vaccine trials has reported that almost 80% of the enrolled women were aged between 18 and 55. As of 5807, there were eighty-four (1.45%) serious AEs reported, but only 2 were considered possibly related to vaccination, a transverse myelitis case and fever, but no specific sex-related AEs were reported [2] . In February 2021, the "Centers for Disease Control and Prevention" (CDC) released data on AEs pertaining to the first month of the COVID-19 vaccine rollout, reporting that women received 61% of the first vaccine doses, whereas 72% of the reported side effects occurred in women [6] . These findings suggest that this higher reactivity of the women immune system should be taken into account. The extremely rare number of cases of ITT following the administration of a single dose of the COVID-19 viral vector vaccine shares many clinical and pathogenetic aspects with another immune-mediated complication affecting a low proportion (0.3 to 4.8%) of patients with previous heparin exposure, the so-called autoimmune heparin-induced thrombocytopenia (HIT) [7, 8] . The ITTs of vaccinated patients have had a relatively high incidence of venous thrombosis in unusual sites, such as the cerebral veins. This is in line with data from an 11-yearobservational study focusing on HIT patients after highdose heparin administration. In fact, out of the 120 consecutive patients enrolled with thrombotic complications, Maria Giulia Mosconi and Francesco Caso contributed equally to this work. * Maria Giulia Mosconi mariagiulia98581@yahoo.it 7 suffered from ischemic cerebrovascular events, 3 from cerebral venous thrombosis, and 1 had a transient confusional state. The overall relative mortality was reported to be much higher in HIT patients with neurologic complications (55%), compared to those patients without neurologic damage (11%) [9] . Both for HIT and adenovirus vector-based DNA vaccines ITT, a key role is played by the platelet-activating antibodies known as anti-PF4-polyanion complexes. Anti-PF4antibodies bind and activate cellular FcγRIIA expressed on platelets and monocytes, leading to a hypercoagulable state and venous thrombotic events [10, 11] . From literature, several cases of HIT in the absence of heparin exposure have been reported, probably triggered by the presence of other polyanions deriving from other molecules, such as chondroitin sulfate, polyphosphates, nucleic acid, bacterial components. Thus, the possible role of viral components, vaccines adjuvants, and/or excipients cannot be excluded [12] . Regarding the ITT case series described by Greinacher et al. [10] , in fact, out of the 11 patients, 2 (18.2%) presented anticardiolipin antibodies, which are typical of Antiphospholipid syndrome (APS). Of note, adenovirus-vector-based DNA-vaccines-ITT also can show several clinical manifestations of severe forms of APS, termed catastrophic APS (CAPS), which can be associated with thrombocytopenia [10, 13] . Some studies have reported that PF4 appeared as the dominant β2GPI binding protein and that the interaction anti-β2GPI-β2GPI-PF4 could probably have been involved in the prothrombotic tendency of APS. In particular, it has been reported that the reactivity in APS was higher against PF4-β2GPI complex than against β2GPI alone. Also, anti-β2GPI-β2GPI-PF4 has been shown thrombo-inflammatory mechanisms as well as the ability to significantly induce platelet p38MAPK phosphorylation and TXB2 production, mainly through F(ab′)2 fragments of antibodies [14] . Moreover, due to peculiar sex and hormonal characteristics [15] [16] [17] , autoimmunity patterns are frequent in young women. In light of the aforementioned, an autoimmune screening may appropriately be considered on young women before administering a viral vector vaccine, in order to reduce the incidence of the ITT and avoid the vaccine underutilization. utm_ source= Commu nicat ions% 2C% 20Pol icy% 20and% 20Res earch & utm_ medium= email & utm_ campa ign= 12303 649_ Presi dent% 27s% 20bul letin% 20% 28spe cial% 20ed% 29% 20-% 2012% 20Apr il% 20202 1& utm_ conte nt= HIT-like% 20eve Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK Sex and gender impact immune responses to vaccines among the elderly Sex differences in vaccine-induced humoral immunity Sex-differential heterologous (non-specific) effects of vaccines: an emerging public health issue that needs to be understood and exploited Sex-based vaccine response in the context of COVID-19 Gender imbalance and risk factor interactions in heparin-induced thrombocytopenia American Society of Hematology 2018 guidelines for management of venous thromboembolism: heparin-induced thrombocytopenia Neurologic complications in immune-mediated heparin-induced thrombocytopenia Thrombotic thrombocytopenia after ChAdOx1 nCov-19 vaccination Heparin-induced thrombocytopenia Heparin-induced thrombocytopenia: a review of new concepts in pathogenesis, diagnosis, and management Women's issues in antiphospholipid syndrome Glycoprotein I ({beta}2GPI) binds platelet factor 4 (PF4): implications for the pathogenesis of antiphospholipid syndrome Antiphospholipid syndrome: complement activation, complement gene mutations, and therapeutic implications Women's issues in antiphospholipid syndrome The Prevalence of Autoimmune Disorders in Women: A Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations